Boundless Bio Past Earnings Performance
Past criteria checks 0/6
Boundless Bio's earnings have been declining at an average annual rate of -17.8%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-17.8%
Earnings growth rate
78.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -32.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Boundless Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -58 | 15 | 50 |
| 31 Mar 24 | 0 | -53 | 13 | 46 |
| 31 Dec 23 | 0 | -49 | 12 | 43 |
| 30 Sep 23 | 0 | -49 | 11 | 42 |
| 30 Jun 23 | 0 | -49 | 10 | 41 |
| 31 Mar 23 | 0 | -47 | 10 | 38 |
| 31 Dec 22 | 0 | -46 | 9 | 37 |
Quality Earnings: BOLD is currently unprofitable.
Growing Profit Margin: BOLD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BOLD's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BOLD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BOLD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: BOLD has a negative Return on Equity (-32.2%), as it is currently unprofitable.